Tempest Therapeutics, Inc. (TPST) Stock
TPST Key Statistics
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
CEO: Matthew Angel. Company website
TPST — Frequently Asked Questions
What is the TPST stock price today?
Tempest Therapeutics, Inc. (TPST) trades at $1.04, up 34.09% on the day, as of Nov 12, 2026 10:46 UTC.
What is Tempest Therapeutics, Inc.'s market cap?
Tempest Therapeutics, Inc. has a market capitalisation of $4.61M, calculated from the live TPST share price and shares outstanding.
What is the P/E ratio of TPST?
TPST has no meaningful price-to-earnings ratio: Tempest Therapeutics, Inc. lost $6.84 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Tempest Therapeutics, Inc. make?
Tempest Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for TPST?
TPST has traded between $0.74 and $2.47 over the past 52 weeks, and the last price is 58.0% below that high.
Is Tempest Therapeutics, Inc. profitable?
Yes. Tempest Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for TPST?
Wall Street analysts rate TPST Buy.
What sector is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Tempest Therapeutics, Inc.?
Matthew Angel is the chief executive of Tempest Therapeutics, Inc., which employs 24 people.
Where can I track TPST in real time?
QFI Terminal shows TPST with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See TPST live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open TPST in Terminal See plans